The FDA May Approve 'Mix-and-Match' Booster Shots as Soon as This Week -- Barrons.com
The FDA May Approve 'Mix-and-Match' Booster Shots as Soon as This Week -- Barrons.com
By Jack Denton
傑克·丹頓(Jack Denton)著
U.S. residents ready for a Covid-19 booster shot may be able to get a different type of vaccine than the dose they initially received.
準備接種新冠肺炎強化注射的美國居民可能會獲得與他們最初接種的疫苗不同類型的疫苗。
The Food and Drug Administration is moving to allow people to take a "mix-and-match" approach to vaccine boosters as soon as this week, according to reports from The Wall Street Journal and the New York Times that cited anonymous sources.
據“華爾街日報”和“紐約時報”援引匿名消息人士的話報道，美國食品和藥物管理局(Food and Drug Administration，簡稱FDA)正採取行動，允許人們最早在本週採取“混合搭配”的方式接種疫苗。
People can currently only receive a booster dose of the same vaccine they initially received. Last Friday, members of the FDA's vaccines advisory committee signaled a readiness to authorize mixed boosters.
人們目前只能接種與最初接種的疫苗相同的加強劑量。上週五，FDA疫苗諮詢委員會的成員表示願意授權混合佐劑。
The FDA won't recommend any one booster over another but will allow people to get a different dose than from their initial vaccination program, the reports said. The regulator may note that using the same vaccine as a booster is preferable when possible, according to the Times, which earlier reported the news.
報道稱，FDA不會推薦任何一種增強劑而不是另一種，但將允許人們獲得與最初疫苗接種計劃不同的劑量。據早些時候報道這一消息的泰晤士報報道，監管機構可能會注意到，在可能的情況下，使用相同的疫苗作為增強劑是更可取的。
Also read: FDA Vaccines Committee Seems Open to Mix-and-Match Boosters. What That Could Look Like.
另請閲讀：FDA疫苗委員會似乎對混合配對推動者持開放態度。那會是什麼樣子。
The Journal report added that the FDA was on track to authorize the vaccines from Moderna (ticker: MRNA) and Johnson & Johnson (JNJ) as booster shots this week.
“華爾街日報”的報道補充説，美國食品藥品監督管理局(FDA)將在本週授權摩德納(股票代碼：mRNA)和強生(JNJ)的疫苗作為增強疫苗。
The regulator has already authorized booster shots of the vaccine from Pfizer (PFE) and its partner BioNTech (BNTX) for seniors and people at high risk of severe illness, as well as for those with compromised immune systems. The shot from Moderna has similarly been greenlit for immunocompromised people.
監管機構已經授權輝瑞(Pfizer)及其合作伙伴BioNTech(BNTX)為老年人和嚴重疾病高危人羣以及免疫系統受損的人注射疫苗。來自莫德納的疫苗同樣也為免疫受損的人開了綠燈。
Allowing a mix-and-match approach has been touted by some health experts and authorities as a way to simplify the logistics of a booster shot rollout. It could also change the dynamics of the vaccine market.
一些健康專家和當局一直吹捧允許混合匹配的方法，認為這是一種簡化助推器注射推出的後勤工作的方式。它還可能改變疫苗市場的動態。
As Barron's Josh Nathan-Kazis wrote last week, "data on the safety and efficacy of mix-and-match boosting will eventually determine how much room there is for other players in the Covid-19 vaccine market." If mix-and-match boosters are widely approved, it bodes well for the makers of Covid-19 vaccines still under development, such as Sanofi (SNY), Novavax (NVAX), and CureVac (CVAC).
正如巴倫公司的喬什·內森-卡齊斯上週所寫的那樣，“關於混合配型疫苗的安全性和有效性的數據最終將決定新冠肺炎疫苗市場上其他參與者還有多大的空間。”如果混合配伍疫苗獲得廣泛認可，對仍在研發中的新冠肺炎疫苗生產商來説是個好兆頭，比如賽諾菲(Sanofi)、諾華(Novavax)和氯氟乙烯(CureVac)。
Write to Jack Denton at jack.denton@dowjones.com
寫信給傑克·丹頓(Jack Denton)，電子郵件：jack.denton@dowjones.com